JHL has completed “mechanical construction” of an off-the-shelf mAb plant in Wuhan, China days after UK regulators gave the go ahead for a trial of its rituximab biosimilar, JHL1101.
Sanofi will tap Japanese academics' personalised medicine knowhow under a new collaboration with the University of Tokyo's translational research initiative (TR).
Bial says BIA 10-2474 met safety and tolerability requirements for human trials, but the firm cannot rule the drug out as the cause of lesions in dogs in a preclinical study.
Heat Biologics will no longer enrol patients in the arm of a Phase II trial examining its cell therapy HS-410 (vesigenurtacel-L) as a monotherapy for bladder cancer.
Anapath has seen a surge in histotechnology services from Europe pharma and rival CROs as consolidation in the preclinical sector has left a lack of capacity for such work.
Researchers at Ohio State University are hiding cancer drugs inside a “molecular Trojan horse” in order to successfully infiltrate drug-resistant cells.
Juno Therapeutics and Fred Hutchinson Cancer Research Center (Fred Hutch) have announced the creation of a new clinical trials unit (CTU) dedicated to immuno-oncology.
International Chemical Investors Group (ICIG) and Novartis Group have entered into an agreement in which ICIG will acquire all shares in Sandoz Industrial Products GmbH.
Unchained Labs has acquired Freeslate, a provider of high-throughput solutions for biologics formulation development and small molecule chemistry – marking the company’s 4th acquisition in 12 months.
Indian drug and API importers can apply for licenses online through a new service launched by the Central Drugs Standards Control Organisation (CDSCO).
Grünenthal has selected Patheon as its preferred development partner for its anti-abuse formulation platform INTAC, based on Hot Melt Extrusion (HME) technology.
Sanofi is poised to terminate its Auvi-Q marketing deal says PDL Biopharma, citing manufacturing issues last year which led to a complete recall of the epinephrine injection product.
Potentially hazardous bio-waste generated at the UK National Biologics Manufacturing Centre (NBMC) in Darlington is being made safe using a bespoke system developed by Suncombe.
Teva has aggressively defended its market share for its blockbuster Copaxone says Momenta, six months after marketing partner Sandoz launched the first generic version in the US.
Research examining how API particle characteristics impact drug stability will help safeguard Denmark’s $12bn (DKK80bn) a year drug manufacturing industry say scientists.
Increased client demand for analytical testing has driven merged CDMO AAIPharma/Cambridge Major Laboratories to invest $11m into a new facility in Missouri.
ScinoPharm Taiwan announced its unaudited financial results for fiscal year 2015, and with it, plans to expand its contract businesses through strategic acquisitions.
Bacterial resistance to ciproflaxin is spreading according to the European CDC which wants the drug industry to invest in development of alternatives to the "last resort" antibiotic.
There are concerns that pharma companies are not fully prepared to meet the new requirements on risk-assessment for excipients, even though the deadline is just a few weeks away.
Capsugel has come on leaps-and-bounds since it was spun-out from Pfizer, the firm says as it inks a deal with Pulmatrix to develop inhaled therapeutics.
Controlled substances and peptides are on AMRI’s wish list as it profits from a growth strategy which has seen six acquisitions over the past two years.
Pharmakon Pharmaceuticals has recalled a batch of morphine after reports three infants reacted badly to the painkiller while being treated in hospital.
Qualicaps has swapped a manufacturing technology customer for dominance of Brazil's fast growing pharmaceutical capsule market through a recent acquisition.
Moving its clinical manufacturing operations to its API and drug site in Queenborough has reduced the risk of problems during tech transfer and cut cycle times according to UK CMO Aesica.
Ennaid Therapeutics has announced it is developing therapeutic cures to help those that may become infected with the Zika Virus, and it may be available in less than four years.
The European Pharmacopoeia Commission (Ph. Eur.) has decided to recruit international experts to ensure the compendium evolves with the globalisation of the pharma industry.
Biocon, an Indian biopharmaceuticals company, has received European approvals for its Rosuvastatin Calcium, a generic equivalent of AstraZeneca’s Crestor tablets.
